Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526926 · ClinicalTrials.gov registry record
A Post-Marketing Observational Study of VYXEOS™
A clinical trial, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 52
- Enrollment target
NCT03526926: Completed study, sponsored by Jazz Pharmaceuticals.
NCT03526926 is a clinical trial that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526926 has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
Primary Outcome
The investigator will assess each AE and indicate if it as an infusion-related reaction.
Interventions
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2020-06-12 |
What the finished NCT03526926 record still lists
NCT03526926 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CPX-351 is the first listed.
NCT03526926 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03526926 about?
NCT03526926 is a clinical study titled "A Post-Marketing Observational Study of VYXEOS™". The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
What is the current status of trial NCT03526926?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2018-10-23. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT03526926?
The interventions under investigation include: CPX-351 (DRUG).
Who is sponsoring clinical trial NCT03526926?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI